The use of memantine as an FDA-approved pharmacological therapy for AD demonstrates the success of treatments that regulate glutamatergic transmission and indicates that other antagonists that target NMDARs may be used to treat symptoms of AD; for example, ifendropil, a selective GluN2B subunit antagonist, could be used to prevent synaptic dysfunction in AD models [141, 142]. This evidence concerns the gene GRIN2B and Alzheimer disease.